Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

NCT03497975 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT03497975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)
Lead sponsor
Trevi Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
August 7, 2018
Completion date
February 24, 2023
Enrollment
353 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis